Published September 30, 2024 | Version v1
Journal article

A case of lenacapavir use for preventing mother-to-child HIV transmission

Contributors

Others:

Description

Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle. Recent findings Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapavir regardless of treatment history. Lenacapavir can be administered orally either daily or weekly and subcutaneously up to every 6 months. In heavily treatment-experienced persons with multidrug-resistant HIV-1 and in treatment-naive persons with HIV-1, lenacapavir in combination with other antiretroviral agents led to high rates of virologic suppression and was well tolerated. Summary Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.

Abstract

International audience

Additional details

Identifiers

URL
https://hal.science/hal-04753282
URN
urn:oai:HAL:hal-04753282v1

Origin repository

Origin repository
UNICA